chr12-12718201-C-T
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The ENST00000228872.9(CDKN1B):c.362C>T(p.Ala121Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000471 in 1,612,932 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A121T) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000228872.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDKN1B | NM_004064.5 | c.362C>T | p.Ala121Val | missense_variant | 1/3 | ENST00000228872.9 | NP_004055.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CDKN1B | ENST00000228872.9 | c.362C>T | p.Ala121Val | missense_variant | 1/3 | 1 | NM_004064.5 | ENSP00000228872 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 152240Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000404 AC: 10AN: 247824Hom.: 0 AF XY: 0.0000446 AC XY: 6AN XY: 134626
GnomAD4 exome AF: 0.0000370 AC: 54AN: 1460574Hom.: 0 Cov.: 39 AF XY: 0.0000454 AC XY: 33AN XY: 726606
GnomAD4 genome AF: 0.000144 AC: 22AN: 152358Hom.: 0 Cov.: 32 AF XY: 0.000201 AC XY: 15AN XY: 74514
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia type 4 Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Sep 01, 2022 | The CDKN1B c.362C>T (p.Ala121Val) missense change has a maximum subpopulation frequency of 0.0083% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in the literature in individuals with multiple endocrine neoplasia type 4. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 121 of the CDKN1B protein (p.Ala121Val). This variant is present in population databases (rs201685429, gnomAD 0.009%). This variant has not been reported in the literature in individuals affected with CDKN1B-related conditions. ClinVar contains an entry for this variant (Variation ID: 404264). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 26, 2024 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Feb 16, 2023 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 33140857) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Mar 04, 2022 | - - |
CDKN1B-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 22, 2024 | The CDKN1B c.362C>T variant is predicted to result in the amino acid substitution p.Ala121Val. This variant has been reported in a breast cancer tumor specimen (Table 3, Viotto et al. 2021. PubMed ID: 33140857). This variant is reported in 0.0083% of alleles in individuals of African descent in gnomAD. It has conflicting interpretations of uncertain significance and likely benign in ClinVar (https://ncbi.nlm.nih.gov/clinvar/variation/404264/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Hereditary cancer-predisposing syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 30, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at